KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Tax Provisions (2016 - 2025)

Historic Tax Provisions for Vertex Pharmaceuticals (VRTX) over the last 15 years, with Q3 2025 value amounting to $215.9 million.

  • Vertex Pharmaceuticals' Tax Provisions rose 2081.7% to $215.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $773.6 million, marking a year-over-year increase of 462.54%. This contributed to the annual value of $784.1 million for FY2024, which is 314.39% up from last year.
  • As of Q3 2025, Vertex Pharmaceuticals' Tax Provisions stood at $215.9 million, which was up 2081.7% from $250.1 million recorded in Q2 2025.
  • Vertex Pharmaceuticals' Tax Provisions' 5-year high stood at $257.9 million during Q4 2022, with a 5-year trough of -$111.2 million in Q2 2021.
  • Moreover, its 5-year median value for Tax Provisions was $192.7 million (2022), whereas its average is $178.6 million.
  • In the last 5 years, Vertex Pharmaceuticals' Tax Provisions tumbled by 78960.0% in 2021 and then surged by 29235.61% in 2022.
  • Over the past 5 years, Vertex Pharmaceuticals' Tax Provisions (Quarter) stood at $100.8 million in 2021, then surged by 155.85% to $257.9 million in 2022, then tumbled by 30.67% to $178.8 million in 2023, then rose by 25.0% to $223.5 million in 2024, then decreased by 3.4% to $215.9 million in 2025.
  • Its Tax Provisions was $215.9 million in Q3 2025, compared to $250.1 million in Q2 2025 and $84.1 million in Q1 2025.